;PMID: 9458091
;source_file_827.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..165] = [t:42..165]
;2)section:[e:169..219] = [t:169..219]
;3)section:[e:223..290] = [t:223..290]
;4)sentence:[e:294..392] = [t:294..392]
;5)sentence:[e:393..672] = [t:393..672]
;6)sentence:[e:673..827] = [t:673..827]
;7)sentence:[e:828..948] = [t:828..948]
;8)sentence:[e:949..1187] = [t:949..1187]
;9)sentence:[e:1188..1958] = [t:1188..1958]
;10)sentence:[e:1959..2066] = [t:1959..2066]
;11)sentence:[e:2067..2290] = [t:2067..2290]
;12)sentence:[e:2291..2343] = [t:2291..2343]
;13)sentence:[e:2344..2523] = [t:2344..2523]
;14)section:[e:2527..2571] = [t:2527..2571]

;section 0 Span:0..36
;Cancer Res. 1998 Feb 1;58(3):468-72.
(SEC
  (FRAG (NN:[0..6] Cancer) (DT:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1998)
        (VBD:[17..20] Feb) (CD:[21..26] 1;58-LRB-) (LS:[26..27] 3)
        (-RRB-:[27..28] -RRB-) (CD:[28..32] :468) (HYPH:[32..33] -)
        (CD:[33..35] 72) (.:[35..36] .)))

;sentence 1 Span:42..165
;Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation
;of  cytochrome P-450 3A and drug interactions.
;[56..66]:substance:"irinotecan"
;[68..74]:substance:"CPT-11"
;[123..142]:cyp450:"cytochrome P-450 3A"
;[147..151]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[42..52] Metabolism))
      (PP (IN:[53..55] of)
        (NP
          (NP (NN:[56..66] irinotecan))
          (NP (-LRB-:[67..68] -LRB-) (NN:[68..74] CPT-11) (-RRB-:[74..75] -RRB-))))
      (PP (IN:[76..78] by)
        (NP (JJ:[79..84] human) (JJ:[85..92] hepatic) (NNS:[93..103] microsomes))))
    (::[103..104] :)
    (NP
      (NP
        (NP (NN:[105..118] participation))
        (PP (IN:[119..121] of)
          (NP
            (NML (NN:[123..133] cytochrome) (NN:[134..139] P-450))
            (NN:[140..142] 3A))))
      (CC:[143..146] and)
      (NP (NN:[147..151] drug) (NNS:[152..164] interactions)))
    (.:[164..165] .)))

;section 2 Span:169..219
;Haaz MC, Rivory L, Riche C, Vernillet L, Robert J.
(SEC
  (FRAG (NNP:[169..173] Haaz) (NNP:[174..176] MC) (,:[176..177] ,)
        (NNP:[178..184] Rivory) (NNP:[185..187] L,) (NNP:[188..193] Riche)
        (NNP:[194..195] C) (,:[195..196] ,) (NNP:[197..206] Vernillet)
        (NNP:[207..209] L,) (NNP:[210..216] Robert) (NNP:[217..219] J.)))

;section 3 Span:223..290
;Institut Bergonie and Universite Victor Segalen Bordeaux 2, France.
(SEC
  (FRAG (NNP:[223..231] Institut) (NNP:[232..240] Bergonie) (CC:[241..244] and)
        (NN:[245..255] Universite) (NNP:[256..262] Victor)
        (NNP:[263..270] Segalen) (NNP:[271..279] Bordeaux) (CD:[280..281] 2)
        (,:[281..282] ,) (NNP:[283..289] France) (.:[289..290] .)))

;sentence 4 Span:294..392
;Irinotecan (CPT-11) is a water-soluble analogue of camptothecin showing
;activity  in colon cancer.
;[294..304]:substance:"Irinotecan"
;[306..312]:substance:"CPT-11"
;[319..324]:substance:"water"
;[333..341]:substance:"analogue"
;[345..357]:substance:"camptothecin"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[294..304] Irinotecan))
      (NP (-LRB-:[305..306] -LRB-) (NN:[306..312] CPT-11)
          (-RRB-:[312..313] -RRB-)))
    (VP (VBZ:[314..316] is)
      (NP-PRD
        (NP
          (NP (DT:[317..318] a)
            (ADJP (NN:[319..324] water) (HYPH:[324..325] -)
                  (JJ:[325..332] soluble))
            (NN:[333..341] analogue))
          (PP (IN:[342..344] of)
            (NP (NN:[345..357] camptothecin))))
        (VP (VBG:[358..365] showing)
          (NP (NN:[366..374] activity))
          (PP (IN:[376..378] in)
            (NP (NN:[379..384] colon) (NN:[385..391] cancer))))))
    (.:[391..392] .)))

;sentence 5 Span:393..672
;Recently, we identified a major metabolite of CPT-11 in  patients' plasma,
;7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
;carbonyloxycamptothecin (APC), which is produced by the oxidation of the
;distal  piperidine ring (P. Rivory et al, Cancer Res., 56: 3689-3694, 1996).
;[425..435]:substance:"metabolite"
;[439..445]:substance:"CPT-11"
;[468..546]:substance:"7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
;carbonyloxycamptothecin"
;[548..551]:substance:"APC"
(SENT
  (S
    (ADVP-TMP (RB:[393..401] Recently))
    (,:[401..402] ,)
    (NP-SBJ (PRP:[403..405] we))
    (VP (VBD:[406..416] identified)
      (NP
        (NP
          (NP (DT:[417..418] a) (JJ:[419..424] major) (NN:[425..435] metabolite))
          (PP (IN:[436..438] of)
            (NP (NN:[439..445] CPT-11))))
        (NP-2 (-NONE-:[445..445] *ICH*)))
      (PP-LOC (IN:[446..448] in)
        (NP
          (NP (NNS:[450..458] patients) (POS:[458..459] '))
          (NN:[460..466] plasma)))
      (,:[466..467] ,)
      (NP-2
        (NP
          (NP
              (NN:[468..521] 7-ethyl-10--LSB-4-N--LRB-5-aminopentanoic-SP-acid-RRB--1-piperidino-RSB-)
              (NN:[523..546] carbonyloxycamptothecin))
          (NP (-LRB-:[547..548] -LRB-) (NN:[548..551] APC)
              (-RRB-:[551..552] -RRB-)))
        (,:[552..553] ,)
        (SBAR
          (WHNP-1 (WDT:[554..559] which))
          (S
            (NP-SBJ-1 (-NONE-:[559..559] *T*))
            (VP (VBZ:[560..562] is)
              (VP (VBN:[563..571] produced)
                (NP-1 (-NONE-:[571..571] *))
                (PP (IN:[572..574] by)
                  (NP-LGS
                    (NP (DT:[575..578] the) (NN:[579..588] oxidation))
                    (PP (IN:[589..591] of)
                      (NP (DT:[592..595] the) (JJ:[596..602] distal)
                          (NN:[604..614] piperidine) (NN:[615..619] ring)))))
                (PRN (-LRB-:[620..621] -LRB-)
                  (FRAG (NNP:[621..623] P.) (NNP:[624..630] Rivory)
                        (FW:[631..633] et) (FW:[634..636] al) (,:[636..637] ,)
                        (NNP:[638..644] Cancer) (NNP:[645..649] Res.)
                        (,:[649..650] ,) (CD:[651..653] 56) (::[653..654] :)
                        (CD:[655..659] 3689) (HYPH:[659..660] -)
                        (CD:[660..664] 3694) (,:[664..665] ,)
                        (CD:[666..670] 1996))
                  (-RRB-:[670..671] -RRB-))))))))
    (.:[671..672] .)))

;sentence 6 Span:673..827
;As with all  active camptothecin derivatives, CPT-11 is subject to
;spontaneous  interconversion between a lactone and a carboxylate form in
;aqueous media.
;[693..705]:substance:"camptothecin"
;[706..717]:substance:"derivatives"
;[719..725]:substance:"CPT-11"
;[779..786]:substance:"lactone"
;[793..804]:substance:"carboxylate"
;[813..826]:substance:"aqueous media"
(SENT
  (S
    (PP (IN:[673..675] As)
      (PP (IN:[676..680] with)
        (NP (DT:[681..684] all) (JJ:[686..692] active)
            (NN:[693..705] camptothecin) (NNS:[706..717] derivatives))))
    (,:[717..718] ,)
    (NP-SBJ (NN:[719..725] CPT-11))
    (VP (VBZ:[726..728] is)
      (ADJP-PRD (NN:[729..736] subject)
        (PP (TO:[737..739] to)
          (NP
            (NP (JJ:[740..751] spontaneous) (NN:[753..768] interconversion))
            (PP (IN:[769..776] between)
              (NP
                (NP (DT:[777..778] a) (NN:[779..786] lactone)
                  (NML (-NONE-:[786..786] *P*)))
                (CC:[787..790] and)
                (NP (DT:[791..792] a) (NN:[793..804] carboxylate)
                  (NML (NN:[805..809] form))))))))
      (PP-LOC (IN:[810..812] in)
        (NP (JJ:[813..820] aqueous) (NNS:[821..826] media))))
    (.:[826..827] .)))

;sentence 7 Span:828..948
;The  kinetics of biotransformation of the two forms of CPT-11 into APC was
;studied  using pooled human liver microsomes.
;[883..889]:substance:"CPT-11"
;[895..898]:substance:"APC"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[828..831] The) (NN:[833..841] kinetics))
      (PP (IN:[842..844] of)
        (NP
          (NP (NN:[845..862] biotransformation))
          (PP (IN:[863..865] of)
            (NP
              (NP (DT:[866..869] the) (CD:[870..873] two) (NNS:[874..879] forms))
              (PP (IN:[880..882] of)
                (NP (NN:[883..889] CPT-11)))))
          (PP (IN:[890..894] into)
            (NP (NN:[895..898] APC))))))
    (VP (VBD:[899..902] was)
      (VP (VBN:[903..910] studied)
        (NP-1 (-NONE-:[910..910] *))
        (S-MNR
          (NP-SBJ (-NONE-:[910..910] *))
          (VP (VBG:[912..917] using)
            (NP (VBN:[918..924] pooled) (JJ:[925..930] human)
                (NN:[931..936] liver) (NNS:[937..947] microsomes))))))
    (.:[947..948] .)))

;sentence 8 Span:949..1187
;The formation of APC was characterized by  the following parameters: Km =
;18.4 +/- 1.4 and 39.7 +/- 11.6 microM; and Vmax =  26.0 +/- 0.6 and 13.4 +/-
;1.7 pmol/min/mg protein for the lactone and  carboxylate forms of CPT-11,
;respectively.
;[966..969]:substance:"APC"
;[1018..1020]:quantitative-name:"Km"
;[1023..1035]:quantitative-value:"18.4 +/- 1.4"
;[1040..1053]:quantitative-value:"39.7 +/- 11.6"
;[1054..1060]:quantitative-units:"microM"
;[1066..1070]:quantitative-name:"Vmax"
;[1074..1086]:quantitative-value:"26.0 +/- 0.6"
;[1091..1103]:quantitative-value:"13.4 +/- 1.7"
;[1104..1115]:quantitative-units:"pmol/min/mg"
;[1116..1123]:substance:"protein"
;[1132..1139]:substance:"lactone"
;[1145..1156]:substance:"carboxylate"
;[1166..1172]:substance:"CPT-11"
(SENT
  (S
    (NP-SBJ-6
      (NP (DT:[949..952] The) (NN:[953..962] formation))
      (PP (IN:[963..965] of)
        (NP (NN:[966..969] APC))))
    (VP (VBD:[970..973] was)
      (VP (VBN:[974..987] characterized)
        (NP-6 (-NONE-:[987..987] *))
        (PP (IN:[988..990] by)
          (NP-LGS
            (NP (DT:[992..995] the) (VBG:[996..1005] following)
                (NNS:[1006..1016] parameters))
            (::[1016..1017] :)
            (S
              (S
                (NP-SBJ (NN:[1018..1020] Km))
                (VP (SYM:[1021..1022] =)
                  (NP
                    (NP
                      (QP (CD:[1023..1027] 18.4) (SYM:[1028..1031] +/-)
                          (CD:[1032..1035] 1.4))
                      (NML-1 (-NONE-:[1035..1035] *P*)))
                    (CC:[1036..1039] and)
                    (NP
                      (QP (CD:[1040..1044] 39.7) (SYM:[1045..1048] +/-)
                          (CD:[1049..1053] 11.6))
                      (NML-1 (NN:[1054..1060] microM))))
                  (PP-4 (-NONE-:[1060..1060] *RNR*))
                  (ADVP-5 (-NONE-:[1060..1060] *RNR*))))
              (::[1060..1061] ;) (CC:[1062..1065] and)
              (S
                (NP-SBJ (NN:[1066..1070] Vmax))
                (VP (SYM:[1071..1072] =)
                  (NP
                    (NP
                      (NP
                        (QP (CD:[1074..1078] 26.0) (SYM:[1079..1082] +/-)
                            (CD:[1083..1086] 0.6))
                        (NML-2 (-NONE-:[1086..1086] *P*)))
                      (CC:[1087..1090] and)
                      (NP
                        (QP (CD:[1091..1095] 13.4) (SYM:[1096..1099] +/-)
                            (CD:[1100..1103] 1.7))
                        (NML-2 (NN:[1104..1108] pmol))))
                    (PP (SYM:[1108..1109] /)
                      (NP (NN:[1109..1112] min)))
                    (PP (SYM:[1112..1113] /)
                      (NP (NN:[1113..1115] mg) (NN:[1116..1123] protein))))
                  (PP-4 (-NONE-:[1123..1123] *RNR*))
                  (ADVP-5 (-NONE-:[1123..1123] *RNR*))))
              (PP-4 (IN:[1124..1127] for)
                (NP
                  (NP (DT:[1128..1131] the)
                    (NML
                      (NML (NN:[1132..1139] lactone)
                        (NML-3 (-NONE-:[1139..1139] *P*)))
                      (CC:[1140..1143] and)
                      (NML (NN:[1145..1156] carboxylate)
                        (NML-3 (NNS:[1157..1162] forms)))))
                  (PP (IN:[1163..1165] of)
                    (NP (NN:[1166..1172] CPT-11)))))
              (,:[1172..1173] ,)
              (ADVP-5 (RB:[1174..1186] respectively)))))))
    (.:[1186..1187] .)))

;sentence 9 Span:1188..1958
;This reaction was found to be  catalyzed principally by cytochrome P-450
;(CYP) 3A because of three key results:  (a) the CYP 3A-selective inhibitors
;ketoconazole (1 microM) and troleandomycin  (100 microM) inhibited APC
;formation by 98 and 100%, respectively, mostly in a  competitive way; (b)
;using microsomes from transfected lymphoblastoid cells  expressing specific
;CYPs, we found that only those from CYP 3A4 cDNA-transfected  cells
;transformed CPT-11 into APC; and (c) using 15 individual preparations of 
;human liver microsomes, we observed highly significant correlations between
;the  activity of CPT-11 metabolism into APC and both immunoreactivity with
;anti-CYP  3A antibodies and testosterone 6beta hydroxylation, an activity
;specifically  mediated by CYP 3A.
;[1244..1269]:cyp450:"cytochrome P-450 (CYP) 3A"
;[1309..1315]:cyp450:"CYP 3A"
;[1326..1336]:substance:"inhibitors"
;[1337..1349]:substance:"ketoconazole"
;[1351..1352]:quantitative-value:"1"
;[1353..1359]:quantitative-units:"microM"
;[1365..1379]:substance:"troleandomycin"
;[1382..1385]:quantitative-value:"100"
;[1386..1392]:quantitative-units:"microM"
;[1404..1407]:substance:"APC"
;[1421..1423]...[1431..1432]:quantitative-value:"98"..."%"
;[1428..1432]:quantitative-value:"100%"
;[1558..1562]:cyp450:"CYPs"
;[1594..1606]:substance:"CYP 3A4 cDNA"
;[1638..1644]:substance:"CPT-11"
;[1650..1653]:substance:"APC"
;[1793..1799]:substance:"CPT-11"
;[1816..1819]:substance:"APC"
;[1851..1874]:substance:"anti-CYP  3A antibodies"
;[1879..1891]:substance:"testosterone"
;[1951..1957]:cyp450:"CYP 3A"
(SENT
  (S
    (NP-SBJ-1 (DT:[1188..1192] This) (NN:[1193..1201] reaction))
    (VP (VBD:[1202..1205] was)
      (VP (VBN:[1206..1211] found)
        (S
          (NP-SBJ-1 (-NONE-:[1211..1211] *))
          (VP (TO:[1212..1214] to)
            (VP (VB:[1215..1217] be)
              (VP (VBN:[1219..1228] catalyzed)
                (NP-1 (-NONE-:[1228..1228] *))
                (ADVP (RB:[1229..1240] principally))
                (PP (IN:[1241..1243] by)
                  (NP-LGS
                    (NML
                      (NML (NN:[1244..1254] cytochrome) (NN:[1255..1260] P-450))
                      (NML (-LRB-:[1261..1262] -LRB-) (NN:[1262..1265] CYP)
                           (-RRB-:[1265..1266] -RRB-)))
                    (NN:[1267..1269] 3A)))))))
        (PP-PRP (IN:[1270..1277] because) (IN:[1278..1280] of)
          (NP
            (NP (CD:[1281..1286] three) (JJ:[1287..1290] key)
                (NNS:[1291..1298] results))
            (::[1298..1299] :)
            (S
              (S
                (LST (LS:[1301..1304] -LRB-a-RRB-))
                (NP-SBJ
                  (NP (DT:[1305..1308] the)
                    (ADJP
                      (NML (NN:[1309..1312] CYP) (NN:[1313..1315] 3A))
                      (HYPH:[1315..1316] -) (JJ:[1316..1325] selective))
                    (NNS:[1326..1336] inhibitors))
                  (NP
                    (NP (NN:[1337..1349] ketoconazole)
                      (PRN (-LRB-:[1350..1351] -LRB-)
                        (NP (CD:[1351..1352] 1) (NN:[1353..1359] microM))
                        (-RRB-:[1359..1360] -RRB-)))
                    (CC:[1361..1364] and)
                    (NP (NN:[1365..1379] troleandomycin)
                      (PRN (-LRB-:[1381..1382] -LRB-)
                        (NP (CD:[1382..1385] 100) (NN:[1386..1392] microM))
                        (-RRB-:[1392..1393] -RRB-)))))
                (VP (VBD:[1394..1403] inhibited)
                  (NP (NN:[1404..1407] APC) (NN:[1408..1417] formation))
                  (PP-EXT (IN:[1418..1420] by)
                    (NP
                      (NP (CD:[1421..1423] 98)
                        (NML-2 (-NONE-:[1423..1423] *P*)))
                      (CC:[1424..1427] and)
                      (NP (CD:[1428..1431] 100)
                        (NML-2 (NN:[1431..1432] %)))))
                  (,:[1432..1433] ,)
                  (ADVP (RB:[1434..1446] respectively))
                  (,:[1446..1447] ,)
                  (PP
                    (ADVP (RB:[1448..1454] mostly))
                    (IN:[1455..1457] in)
                    (NP (DT:[1458..1459] a) (JJ:[1461..1472] competitive)
                        (NN:[1473..1476] way)))))
              (::[1476..1477] ;)
              (S
                (LST (LS:[1478..1481] -LRB-b-RRB-))
                (S-MNR
                  (NP-SBJ (-NONE-:[1481..1481] *))
                  (VP (VBG:[1482..1487] using)
                    (NP
                      (NP (NNS:[1488..1498] microsomes))
                      (PP (IN:[1499..1503] from)
                        (NP
                          (NP (VBN:[1504..1515] transfected)
                              (JJ:[1516..1530] lymphoblastoid)
                              (NNS:[1531..1536] cells))
                          (VP (VBN:[1538..1548] expressing)
                            (NP (JJ:[1549..1557] specific)
                                (NNS:[1558..1562] CYPs))))))))
                (,:[1562..1563] ,)
                (NP-SBJ (PRP:[1564..1566] we))
                (VP (VBD:[1567..1572] found)
                  (SBAR (IN:[1573..1577] that)
                    (S
                      (NP-SBJ
                        (NP (RB:[1578..1582] only) (DT:[1583..1588] those))
                        (PP (IN:[1589..1593] from)
                          (NP
                            (ADJP
                              (NML
                                (NML (NN:[1594..1597] CYP) (NN:[1598..1601] 3A4))
                                (NN:[1602..1606] cDNA))
                              (HYPH:[1606..1607] -)
                               (VBN:[1607..1618] transfected))
                            (NNS:[1620..1625] cells))))
                      (VP (VBD:[1626..1637] transformed)
                        (NP (NN:[1638..1644] CPT-11))
                        (PP (IN:[1645..1649] into)
                          (NP (NN:[1650..1653] APC))))))))
              (::[1653..1654] ;) (CC:[1655..1658] and)
              (S
                (LST (LS:[1659..1662] -LRB-c-RRB-))
                (S-MNR
                  (NP-SBJ (-NONE-:[1662..1662] *))
                  (VP (VBG:[1663..1668] using)
                    (NP
                      (NP (CD:[1669..1671] 15) (JJ:[1672..1682] individual)
                          (NNS:[1683..1695] preparations))
                      (PP (IN:[1696..1698] of)
                        (NP (JJ:[1700..1705] human) (NN:[1706..1711] liver)
                            (NNS:[1712..1722] microsomes))))))
                (,:[1722..1723] ,)
                (NP-SBJ (PRP:[1724..1726] we))
                (VP (VBD:[1727..1735] observed)
                  (NP
                    (NP (RB:[1736..1742] highly) (JJ:[1743..1754] significant)
                        (NNS:[1755..1767] correlations))
                    (PP (IN:[1768..1775] between)
                      (NP
                        (NP
                          (NP (DT:[1776..1779] the) (NN:[1781..1789] activity))
                          (PP (IN:[1790..1792] of)
                            (NP (NN:[1793..1799] CPT-11)
                                (NN:[1800..1810] metabolism)))
                          (PP (IN:[1811..1815] into)
                            (NP (NN:[1816..1819] APC))))
                        (CC:[1820..1823] and)
                        (NP (CC:[1824..1828] both)
                          (NP
                            (NP (NN:[1829..1845] immunoreactivity))
                            (PP (IN:[1846..1850] with)
                              (NP
                                (NML (AFX:[1851..1855] anti)
                                     (HYPH:[1855..1856] -) (NN:[1856..1859] CYP)
                                     (NN:[1861..1863] 3A))
                                (NNS:[1864..1874] antibodies))))
                          (CC:[1875..1878] and)
                          (NP
                            (NP (NN:[1879..1891] testosterone)
                                (NN:[1892..1897] 6beta)
                                (NN:[1898..1911] hydroxylation))
                            (,:[1911..1912] ,)
                            (NP
                              (NP (DT:[1913..1915] an)
                                  (NN:[1916..1924] activity))
                              (VP
                                (ADVP (RB:[1925..1937] specifically))
                                (VBN:[1939..1947] mediated)
                                (NP (-NONE-:[1947..1947] *))
                                (PP (IN:[1948..1950] by)
                                  (NP-LGS (NN:[1951..1954] CYP)
                                          (NN:[1955..1957] 3A)))))))))))))))))
    (.:[1957..1958] .)))

;sentence 10 Span:1959..2066
;The effect on this metabolism of 11 drugs used at 100 microM  was studied
;with CPT-11 lactone at 25 microM.
;[1995..2000]:substance:"drugs"
;[2009..2012]:quantitative-value:"100"
;[2013..2019]:quantitative-units:"microM"
;[2038..2052]:substance:"CPT-11 lactone"
;[2056..2058]:quantitative-value:"25"
;[2059..2065]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1959..1962] The) (NN:[1963..1969] effect))
      (PP (IN:[1970..1972] on)
        (NP (DT:[1973..1977] this) (NN:[1978..1988] metabolism)))
      (PP (IN:[1989..1991] of)
        (NP
          (NP (CD:[1992..1994] 11) (NNS:[1995..2000] drugs))
          (VP (VBN:[2001..2005] used)
            (NP (-NONE-:[2005..2005] *))
            (PP (IN:[2006..2008] at)
              (NP (CD:[2009..2012] 100) (NN:[2013..2019] microM)))))))
    (VP (VBD:[2021..2024] was)
      (VP (VBN:[2025..2032] studied)
        (NP-1 (-NONE-:[2032..2032] *))
        (PP (IN:[2033..2037] with)
          (NP
            (NP (NN:[2038..2044] CPT-11) (NN:[2045..2052] lactone))
            (PP (IN:[2053..2055] at)
              (NP (CD:[2056..2058] 25) (NN:[2059..2065] microM)))))))
    (.:[2065..2066] .)))

;sentence 11 Span:2067..2290
;Amikacin, Bactrim, ciprofloxacin,  rocephine, 5-fluorouracil, metoclopramide,
;morphine, and paracetamol had no  effect, but ondansetron, loperamide, and
;racecadotril inhibited this pathway by  25, 50, and 50%, respectively.
;[2067..2075]:substance:"Amikacin"
;[2077..2084]:substance:"Bactrim"
;[2086..2099]:substance:"ciprofloxacin"
;[2102..2111]:substance:"rocephine"
;[2113..2127]:substance:"5-fluorouracil"
;[2129..2143]:substance:"metoclopramide"
;[2145..2153]:substance:"morphine"
;[2159..2170]:substance:"paracetamol"
;[2191..2202]:substance:"ondansetron"
;[2204..2214]:substance:"loperamide"
;[2220..2232]:substance:"racecadotril"
;[2260..2262]...[2274..2275]:quantitative-value:"25"..."%"
;[2264..2266]...[2274..2275]:quantitative-value:"50"..."%"
;[2272..2275]:quantitative-value:"50%"
(SENT
  (S
    (S
      (NP-SBJ (NN:[2067..2075] Amikacin) (,:[2075..2076] ,)
              (NN:[2077..2084] Bactrim) (,:[2084..2085] ,)
              (NN:[2086..2099] ciprofloxacin) (,:[2099..2100] ,)
              (NN:[2102..2111] rocephine) (,:[2111..2112] ,)
              (NN:[2113..2127] 5-fluorouracil) (,:[2127..2128] ,)
              (NN:[2129..2143] metoclopramide) (,:[2143..2144] ,)
              (NN:[2145..2153] morphine) (,:[2153..2154] ,)
              (CC:[2155..2158] and) (NN:[2159..2170] paracetamol))
      (VP (VBD:[2171..2174] had)
        (NP (DT:[2175..2177] no) (NN:[2179..2185] effect))))
    (,:[2185..2186] ,) (CC:[2187..2190] but)
    (S
      (NP-SBJ (NN:[2191..2202] ondansetron) (,:[2202..2203] ,)
              (NN:[2204..2214] loperamide) (,:[2214..2215] ,)
              (CC:[2216..2219] and) (NN:[2220..2232] racecadotril))
      (VP (VBD:[2233..2242] inhibited)
        (NP (DT:[2243..2247] this) (NN:[2248..2255] pathway))
        (PP-EXT (IN:[2256..2258] by)
          (NP
            (NP (CD:[2260..2262] 25)
              (NML-1 (-NONE-:[2262..2262] *P*)))
            (,:[2262..2263] ,)
            (NP (CD:[2264..2266] 50)
              (NML-1 (-NONE-:[2266..2266] *P*)))
            (,:[2266..2267] ,) (CC:[2268..2271] and)
            (NP (CD:[2272..2274] 50)
              (NML-1 (NN:[2274..2275] %)))))
        (,:[2275..2276] ,)
        (ADVP (RB:[2277..2289] respectively))))
    (.:[2289..2290] .)))

;sentence 12 Span:2291..2343
;These concentrations exceed those expected in  vivo.
(SENT
  (S
    (NP-SBJ (DT:[2291..2296] These) (NNS:[2297..2311] concentrations))
    (VP (VBP:[2312..2318] exceed)
      (NP
        (NP (DT:[2319..2324] those))
        (VP (VBN:[2325..2333] expected)
          (NP (-NONE-:[2333..2333] *))
          (ADVP (FW:[2334..2336] in) (FW:[2338..2342] vivo)))))
    (.:[2342..2343] .)))

;sentence 13 Span:2344..2523
;APC formation in patients may thus be influenced by coadministered 
;ketoconazole therapy and may decline after administration of CPT-11 because
;of  the lactonolysis of the latter.
;[2344..2347]:substance:"APC"
;[2412..2424]:substance:"ketoconazole"
;[2473..2479]:substance:"CPT-11"
;[2516..2522]:substance:"latter"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[2344..2347] APC) (NN:[2348..2357] formation))
      (PP-LOC (IN:[2358..2360] in)
        (NP (NNS:[2361..2369] patients))))
    (VP
      (VP (MD:[2370..2373] may)
        (ADVP (RB:[2374..2378] thus))
        (VP (VB:[2379..2381] be)
          (VP (VBN:[2382..2392] influenced)
            (NP-1 (-NONE-:[2392..2392] *))
            (PP (IN:[2393..2395] by)
              (NP-LGS (VBN:[2396..2410] coadministered)
                      (NN:[2412..2424] ketoconazole) (NN:[2425..2432] therapy))))))
      (CC:[2433..2436] and)
      (VP (MD:[2437..2440] may)
        (VP (VB:[2441..2448] decline)
          (PP-TMP (IN:[2449..2454] after)
            (NP
              (NP (NN:[2455..2469] administration))
              (PP (IN:[2470..2472] of)
                (NP (NN:[2473..2479] CPT-11)))))
          (PP (IN:[2480..2487] because) (IN:[2488..2490] of)
            (NP
              (NP (DT:[2492..2495] the) (NN:[2496..2508] lactonolysis))
              (PP (IN:[2509..2511] of)
                (NP (DT:[2512..2515] the) (JJ:[2516..2522] latter))))))))
    (.:[2522..2523] .)))

;section 14 Span:2527..2571
;PMID: 9458091 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2527..2531] PMID) (::[2531..2532] :) (CD:[2533..2540] 9458091)
        (-LRB-:[2541..2542] -LSB-) (NNP:[2542..2548] PubMed)
        (HYPH:[2549..2550] -) (NN:[2551..2558] indexed) (IN:[2559..2562] for)
        (NNP:[2563..2570] MEDLINE) (-RRB-:[2570..2571] -RSB-)))
